Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 2 study of LNP023 in C3 glomerulopathy
2017-000889-29Phase 2Unknown
- Sponsor
- Novartis
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Iptacopan in Complement 3 glomerulopathy (C3G) (2 cohorts), sponsored by Novartis. Primary endpoint: Primary - Cohort A: Change from baseline in UPCR at Week 12. Status: unknown.
02
Drugs
Iptacopan
03
Conditions
Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on 2017-000889-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000889-29.